Find a Physician | How to Contribute | About Us | Clinical Trials
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CMEK162AUS11

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local
Principal Investigator
Young Chae
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CMEK162AUS11
The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
MEK162 is a drug that is being developed for the potential treatment of different tumor types and/or blood malignancies. MEK162 is a new type of drug that works by slowing down an important pathway (RAS/RAF/MEK) inside the cell involved in the development of certain types of cancers. This pathway (RAS/RAF/MEK) is thought to play a role in cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Some of the eligibility criteria include:
  • Study participants must have a confirmed diagnosis of a select solid tumor (except for pancreatic cancer, biliary cancer, colorectal cancer, low grade serous ovarian cancer, melanoma) or hematologic malignancy.
  • Participants must have had at least one prior treatment for cancer and it has returned (recurred) or it has spread beyond the initial cancer location (the cancer is metastatic and/or is locally advanced).
  • Participants must have cancer for which no standard therapy options are anticipated to result in a lasting remission.
  • Participants must have a tumor with a mutation in RAF, RAS, NF1 or MEK. This is determined by genetic testing.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
In this study, a complete dosing cycle is 28 days. In each cycle, participants will take MEK162 twice a day, by mouth. Participants may continue to receive study drug unless they and/or the study doctor decide to stop the study drug dosing.
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Young Chae

last updated: 05-Oct-15 08:19 PM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.